1Laufs U,Fata VL,Pluteky J,et al.Upregulation of endothelial nitric oxide synthase by HMG-CoA reductase inhibitors.Circulation,1998,97:1129
2Krone W,Muller WD.Lipid lowering therapy and stabilization of atherosclerotic plaques.Thromb-Haemost,1999,82(suppl.1):60
3Haffner SM,Lehto S,Ronneman T,et al.Mortality from coronary heart disease in subjects with type 2 diabetes and in non-diabetic subjects with and without prior myocardial infarction.N Engl J Med,1998,339:229
4Vogel RA, Benitez RM. Noninvasive assessment of cardiovascular risk:from Framingham to the future- Rev Cardiovasc Med,2000,1 (1) :34 - 42.
5Celis H, Fagard RH, Steessen JA, et al. Risk and benefit of treatment of isolated systolic hypertension in the elderly: evidence from the Systolic Hypertension in Europe Trial. Curr Opin Cardiol, 2001,16(6):342- 8.
6Leonetti G, Zanchetti A. Results of antihypertensive treatment trials in the elderly. Am J Geriatr Cardiol, 2002,11 ( 1 ) :41 - 47.
7Wang JG, Staessen JA, Gong L, et al. Chinese trial on isolated systolic hypertension in the elderly. Systolic Hypertension in China (Syst-China)Collaborative Group.Arch Intern Med, 2000,24;160(2):211- 220.
8Adams HP. New strategies for prevention of ischemic stroke:The LIFE Study. Curr Neurol Neurosei Rep, 2003,3 (10) :46 - 51.
9Sleight P, Yusuf S, Pogue J, et al. Blood-pressure reduction and cardiovascular risk in HOPE study. Lancet, 2001,22 - 29 ;358(9299) :2130 - 1.
10Muhlhauser I. Blood pressure and cardiovascular risk in the HOPE study. Lancet,2002,15;359(9323) :2118.
